Drug
Moxifloxacin (M)
Moxifloxacin (M) is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_2
2
50%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Recruiting2
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (50.0%)
Phase 31 (25.0%)
N/A1 (25.0%)
Trials by Status
recruiting250%
completed125%
not_yet_recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_3
A PAN-USR TB Multi-Center Trial
NCT06905522
recruitingphase_2
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
NCT06114628
not_yet_recruitingnot_applicable
A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
NCT07126639
completedphase_2
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
NCT01498419
Clinical Trials (4)
Showing 4 of 4 trials
NCT06905522Phase 3
A PAN-USR TB Multi-Center Trial
NCT06114628Phase 2
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
NCT07126639Not Applicable
A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis
NCT01498419Phase 2
Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4